AHA Scientific Sessions 2023 Late-Breaking Science Coverage
Published: 30 October 2023
-
Views:
2234
-
Likes:
7
-
Views:
2234
-
Likes:
7
-
Up Next -
19m 41sPart 2 | Session 3 AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program -
21m 35sPart 2 | Session 4 AHA 23 Late-Breaker Discussion: The SELECT Trial
-
3m 11s -
6m 55sPart 3 | Session 2 ECLS-SHOCK: Impact of Cardiac Arrest on the Efficacy of ECLS Patients -
5m 4s -
3m 54sPart 3 | Session 4 Nicotinamide Riboside in PAD for Improved Walking -
8m 27sPart 3 | Session 5 SPECIAL: Ultrasound-assisted Thrombolysis Vs Pulmonary Embolectomy for PE -
4m 59s -
10m -
6m 55s -
10m 9sPart 3 | Session 9 JEWEL-IDE: Jewel P-WCD in Pts at High Risk of Cardiac Arrest -
4m 59s -
5m 4s
-
7m 3sPart 4 | Session 1 Preventive Cardiology Highlights in 2023 -
10m 59sPart 4 | Session 2 3 Trials That Will Change My Practice With Dr Parwani -
7m 20sPart 4 | Session 3 3 Trials That Will Change My Practice With Dr Itchhaporia
-
2mPart 5 | Session 1 Solving Problems with Dr Pugazhendi Vijayaraman -
1m 36sPart 5 | Session 2 Advice for Early-Career Researchers With Dr Demilade Adedinsewo -
39sPart 5 | Session 3 Making a Difference with Dr Alexander Fanaroff
-
23m 13sPart 1 | Session 1 View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
12m 34sPart 1 | Session 2 View from the Thoraxcenter: AHA 23 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
22m 30sPart 2 | Session 1 AHA 23 Late-Breaker Discussion: The ARIES HM3 Clinical Trial Mandeep Mehra, Harriette Van Spall
Overview
Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.
In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.
Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.
Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.
Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.
More from this programme
Part 1
View from the Thoraxcenter
In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23.
Part 2
Late-Breaker Discussions with Harriette Van Spall
Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.
Part 3
Expert Interviews
Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.
Part 4
Highlights
About the episode
AHA 2023 — Investigators, Prof Stefan James and Prof Jonas Oldgren (Uppsala University, SE) discuss the findings of the DAPA-MI trial (NCT04564742) with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA).
This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo, given once daily in addition to standard of care therapy (SoC), on death, hospitalization for HF (HHF) and other cardiometabolic outcomes. 4017 patients were enrolled in the study which excluded participants with known diabetes.
Results presented at AHA 2023 showed that dapagliflozin demonstrated significant benefit in patients with acute MI and impaired left ventricular systolic dysfunction, without diabetes or CHF in regards to improvement in cardiometabolic outcomes as compared to placebo. This effect was consistent across all prespecified subgroups, with no new safety concerns. Clinical event rates were low with no significant difference between randomized groups.
Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Stefan James
Professor of Cardiology
Prof Stefan James is Professor of Cardiology at Uppsala University, Scientific Director of Uppsala Clinical Research Center and a senior Interventional Cardiologist at Uppsala University Hospital in Sweden. He is the president of the Swedish society of Cardiology and a Fellow of the ESC.
He graduated from Uppsala University Medical School and completed specialist training in Uppsala. He has previously held positions at the Karolinska Hospital, the University Hospital Örebro and Duke Clinical Research Institute, Duke University.
Comments